|
| 36595552 | ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC). | PLoS Genet | 2023 |
| 38001424 | Modulation of SLFN11 induces changes in DNA Damage response in breast cancer. | Cancer Cell Int | 2023 |
| 37556775 | Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial. | J Clin Oncol | 2023 |
| 37609714 | DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancer. | Future Oncol | 2023 |
| 36901733 | Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World Setting. | Int J Mol Sci | 2023 |
| 37265183 | Complete pathological response of hormone receptor positive invasive breast cancer in a patient with multiple myeloma treated with ixazomib. | Tumori | 2023 |
| 37202560 | An integrated tumor, immune and microbiome atlas of colon cancer. | Nat Med | 2023 |
| 36931614 | Standard Operating Procedures (SOPs) for non-invasive multiple biomarkers detection in an academic setting: A critical review of the literature for the RENOVATE study protocol. | Crit Rev Oncol Hematol | 2023 |
| 36980315 | Freehand 1.5T MR-Guided Vacuum-Assisted Breast Biopsy (MR-VABB): Contribution of Radiomics to the Differentiation of Benign and Malignant Lesions. | Diagnostics (Basel) | 2023 |
| 36595552 | ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC). | PLoS Genet | 2023 |
| 37556775 | Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial. | J Clin Oncol | 2023 |
| 38001424 | Modulation of SLFN11 induces changes in DNA Damage response in breast cancer. | Cancer Cell Int | 2023 |
| 37609714 | DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancer. | Future Oncol | 2023 |
| 36980315 | Freehand 1.5T MR-Guided Vacuum-Assisted Breast Biopsy (MR-VABB): Contribution of Radiomics to the Differentiation of Benign and Malignant Lesions. | Diagnostics (Basel) | 2023 |
| 37202560 | An integrated tumor, immune and microbiome atlas of colon cancer. | Nat Med | 2023 |
| 37265183 | Complete pathological response of hormone receptor positive invasive breast cancer in a patient with multiple myeloma treated with ixazomib. | Tumori | 2023 |
| 36931614 | Standard Operating Procedures (SOPs) for non-invasive multiple biomarkers detection in an academic setting: A critical review of the literature for the RENOVATE study protocol. | Crit Rev Oncol Hematol | 2023 |
| 36901733 | Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World Setting. | Int J Mol Sci | 2023 |
| 35292180 | Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues. | Gynecol Oncol | 2022 |
| 36367935 | High-temporal resolution profiling reveals distinct immune trajectories following the first and second doses of COVID-19 mRNA vaccines. | Sci Adv | 2022 |
| 35902421 | HLA-G as a prognostic marker in stage II/III colorectal cancer: not quite there yet. | Histochem Cell Biol | 2022 |
| 36228963 | Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. | Ann Oncol | 2022 |
| 35885477 | The Multidisciplinary Approach of Rectal Cancer: The Experience of "COMRE Group" Model. | Diagnostics (Basel) | 2022 |
| 35568887 | Incidence and immunomic features of apyretic COVID-19 in patients affected by solid tumors: a prospective cohort study. | J Transl Med | 2022 |
| 35927391 | The association between adiposity and anti-proliferative response to neoadjuvant endocrine therapy with letrozole in post-menopausal patients with estrogen receptor positive breast cancer. | NPJ Breast Cancer | 2022 |
| 35793549 | Impact of obesity and white adipose tissue inflammation on the omental microenvironment in endometrial cancer. | Cancer | 2022 |
| 36555667 | Ataxia-Telangiectasia Mutated Loss of Heterozygosity in Melanoma. | Int J Mol Sci | 2022 |
| 35292180 | Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues. | Gynecol Oncol | 2022 |
| 35201850 | Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer. | JCO Precis Oncol | 2022 |
| 35172272 | Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. | Eur J Cancer | 2022 |
| 35241537 | The Margins' Challenge: Risk Factors of Residual Disease After Breast Conserving Surgery in Early-stage Breast Cancer. | In Vivo | 2022 |
| 35793549 | Impact of obesity and white adipose tissue inflammation on the omental microenvironment in endometrial cancer. | Cancer | 2022 |
| 35568887 | Incidence and immunomic features of apyretic COVID-19 in patients affected by solid tumors: a prospective cohort study. | J Transl Med | 2022 |
| 36555667 | Ataxia-Telangiectasia Mutated Loss of Heterozygosity in Melanoma. | Int J Mol Sci | 2022 |
| 35902421 | HLA-G as a prognostic marker in stage II/III colorectal cancer: not quite there yet. | Histochem Cell Biol | 2022 |
| 36367935 | High-temporal resolution profiling reveals distinct immune trajectories following the first and second doses of COVID-19 mRNA vaccines. | Sci Adv | 2022 |
| 35927391 | The association between adiposity and anti-proliferative response to neoadjuvant endocrine therapy with letrozole in post-menopausal patients with estrogen receptor positive breast cancer. | NPJ Breast Cancer | 2022 |
| 36228963 | Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. | Ann Oncol | 2022 |
| 35885477 | The Multidisciplinary Approach of Rectal Cancer: The Experience of "COMRE Group" Model. | Diagnostics (Basel) | 2022 |
| 35241537 | The Margins' Challenge: Risk Factors of Residual Disease After Breast Conserving Surgery in Early-stage Breast Cancer. | In Vivo | 2022 |
| 35201850 | Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer. | JCO Precis Oncol | 2022 |
| 35172272 | Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. | Eur J Cancer | 2022 |
| 33402520 | Breast Cancer Surgery in the COVID-19 Pandemic: Validation of a Preventive Program for Patients and Health Care Workers. | In Vivo | 2021 |
| 34183353 | Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. | Cancer Discov | 2021 |
| 34281208 | Multi-Gene Testing Overview with a Clinical Perspective in Metastatic Triple-Negative Breast Cancer. | Int J Mol Sci | 2021 |
| 33721561 | 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. | Lancet Oncol | 2021 |
| 34301749 | Niraparib for Advanced Breast Cancer with Germline <i>BRCA1</i> and <i>BRCA2</i> Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study. | Clin Cancer Res | 2021 |
| 34298675 | Assessment of Circulating Nucleic Acids in Cancer: From Current Status to Future Perspectives and Potential Clinical Applications. | Cancers (Basel) | 2021 |
| 34025586 | Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective. | Front Endocrinol (Lausanne) | 2021 |
| 33408218 | Prospective validation study of prognostic biomarkers to predict adverse outcomes in patients with COVID-19: a study protocol. | BMJ Open | 2021 |